AEON Biopharma reports positive biosimilarity data for ABP-450, raises $6M PIPE, reduces debt 90%

AEON Biopharma, Inc.

Initial analytical results confirm 100% amino-acid sequence match to BOTOX and highly similar functional characteristics.
FDA BPD Type 2a meeting provided clear framework for remaining analytical comparability program; majority to be completed in 2026.
Completed $6M PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90%.
Appointed John Bencich as CFO; cash of $3.0M at Dec 31, 2025 plus $4.2M Jan PIPE proceeds expected to fund ops into Q3 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AEON Biopharma, Inc. reported financial results for the year ended December 31, 2025.

Period: the year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 30, 2026, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the year ended December 31, 2025.

View on SEC.gov

1428 earnings releases filed in the last 30 days. Browse all earnings releases →

AEON Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001837607-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.